정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2501 | Recruiting | A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19. | COVID-19 | Drug: APX-115 Drug: Placebo |
Phase 2 | Aptabio Therapeutics, Inc., Covance | INDIV | 80 | All | 18 Years ~ 80 Years | Alternative Research Associates, LLC, Hialeah, Florida, United States Anne Arundel Medical Center, Baltimore, Maryland, United States Millennium Physicians Group, Houston, Texas, United States |
| 2500 | Active, not recruiting | A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults | Covid19 | Drug: RTB101 Drug: Placebo |
Phase 2 | Restorbio Inc., National Institute on Aging (NIA) | INDUSTRY | 60 | All | 65 Years | University of Connecticut, UConn Center on Aging, Farmington, Connecticut, United States Hebrew Senior Life, Marcus Institute for Aging Research, Roslindale, Massachusetts, United States |
| 2499 | Suspended | A Phase 2 Study to Evaluate Axatilimab for Hospitalized Patients With Respiratory Involvement Secondary to COVID-19 | Cytokine Release Syndrome | Drug: SNDX-6352 Drug: Placebo |
Phase 2 | Syndax Pharmaceuticals | INDUSTRY | 186 | All | 18 Years | HonorHealth, Scottsdale, Arizona, United States Montefiore Medical Center, Bronx, New York, United States |
| 2498 | Recruiting | A Phase 2 Study to Evaluate Biomarker Change, Efficacy, Pharmacokinetics, Safety and Tolerability of Telacebec (Q203) in Covid-19 Patients | COVID-19 Virus Infection | Drug: Telacebec Drug: COVID-19 Standard of care |
Phase 2 | Qurient Co., Ltd. | INDUSTRY | 66 | All | 18 Years | Chris Hani Baragwanath Academic Hospital, Soweto, Gauteng, South Africa KwaPhila Health Solutions, Durban, Kwa-Zula Natal, South Africa TASK Eden, George, Western Cape, South Africa |
| 2497 | Completed | A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19). | COVID-19 | Drug: Infliximab | Phase 2 | Tufts Medical Center, National Institutes of Health (NIH) | OTHER | 17 | All | 18 Years | Tufts Medical Center, Boston, Massachusetts, United States |
| 2496 | Recruiting | A Phase 2/3, Randomized, Double Blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of FP-025 in Patients With Severe to Critical COVID 19 With Associated Acute Respiratory Distress Syndrome (ARDS) | Severe to Critical Coronavirus (CoV) Disease 2019 (COVID 19) With Associated Acute Respiratory Distress Syndrome (ARDS) | Drug: FP-025 100 mg Drug: FP-025 300 mg Drug: Placebo |
Phase 3 | Foresee Pharmaceuticals Co., Ltd. | INDUSTRY | 403 | All | 18 Years | Velocity Chula Vista, Chula Vista, California, United States Velocity San Diego, La Mesa, California, United States Shady Grove Medical Center, Rockville, Maryland, United States University of Nevada, Las Vegas (UNLV) School of Medicine, Las Vegas, Nevada, United States Trinity Health Center, Minto, North Dakota, United States Legacy Health, Portland, Oregon, United States United Medical Memorial Hospital, Houston, Texas, United States |
| 2495 | Recruiting | A Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study, Evaluating Efficacy and Safety of Allocetra-OTS in Patients With Severe or Critical COVID-19 With Associated Acute Respiratory Distress Syndrome (ARDS) | Covid19 | Drug: ALLOCETRA-OTS Other: Placebo |
Phase 2 | Enlivex Therapeutics Ltd. | INDUSTRY | 152 | All | 18 Years ~ 85 Years | Hadassah Ein Kerem Medical Center, Jerusalem, Israel |
